
ZVRA Stock Forecast & Price Target
ZVRA Analyst Ratings
Bulls say
Zevra Therapeutics Inc. demonstrates a robust growth trajectory with a significant increase in patient enrollment for its MIPLYFFA therapy, rising from 90 to 109 treatment requests by the end of 2024, signaling strong market demand. The company reported impressive sales of $10.1 million in the fourth quarter of 2024, significantly surpassing estimates, indicating successful initial market penetration for its ultra-rare Niemann-Pick type C treatment. Additionally, ongoing awareness campaigns among healthcare providers and a potential European filing in the second half of 2025 further support a positive outlook for sustained revenue growth into 2025.
Bears say
Zevra Therapeutics Inc. reported a significant GAAP net loss of $20.4 million, coupled with additional non-cash expenses that further strained financial performance, raising concerns about the sustainability of its operations. Challenges such as poor payer coverage, potential adverse impacts from recent competitor approvals, and emerging safety issues are expected to hinder the market performance and growth potential of its key product, Miplyffa. Furthermore, the company has a history of ongoing losses and lacks a proven pathway to profitability, posing risks to its commercial viability and investor confidence in future developments.
This aggregate rating is based on analysts' research of Zevra Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ZVRA Analyst Forecast & Price Prediction
Start investing in ZVRA
Order type
Buy in
Order amount
Est. shares
0 shares